Overview
◆Date: October 4th, 2023
◆Time: 5:30 - 7:00 PM (PT) | 8:30-10:00 PM(ET)
◆Format: Zoom Webinar
◆Fee: Free 
※We only accept registrations with company email addresses.
※Please refrain from using a free email address or a person from a law firm.

◆Summary:
O’Melveny & Myers partners Rob Shaffer, Pete Herrick, and Steve McIntyre discuss hot topics and trends at the intersection of antitrust and intellectual property law. The webinar will cover legal developments and litigation risks facing life sciences companies (including antitrust challenges to patent settlement agreements), antitrust policy under the Biden administration, and the U.S. Department of Justice and Federal Trade Commission’s recent enforcement actions in IP-intensive industries, among other subjects.



◆Agenda:
Part1 Panelist Introduction
 5:30-5:35 PM (PT) | 8:30-8:35 PM(ET) | 09:30-09:35 AM (JST)
Part2 Lecture
 "U.S. Antitrust and Intellectual Property Law: Current Issues & Trends"
 5:35-6:35 PM (PT) | 8:35-9:35 PM(ET) | 09:35-10:35 AM (JST)
Part3 Moderated Discussion
 6:35-6:50 PM (PT) | 9:35-9:50 PM(ET) | 10:35-10:50 AM (JST)
Part4 Q&A session
 6:50-7:00 PM (PT) | 9:50-10:00 PM (ET) | 10:50-11:00 AM(JST)





◆Speakers:

231005_O'Melveny-Myers-LLP_Rob Shaffer.jpg   

Partner
(O'Melveny & Myers LLP)

Rob Shaffer is a nationally recognized first-chair IP trial lawyer with extensive experience handling complex patent litigation in the most important intellectual property matters. For more than 20 years, Rob has represented some of the world’s most innovative pharmaceutical and medical device companies in dozens of major cases, including Hatch-Waxman disputes, International Trade Commission (ITC) actions, and complex commercial arbitrations. He also represents clients before the Patent Trial and Appeal Board (PTAB) of the US Patent and Trademark Office (USPTO).

Rob advises clients through every step of patent litigation—from pre-trial counseling to leading trial teams, and through appeal. Along with his life sciences work, Rob also represents clients in other technologies, including consumer electronics, software, and gaming companies in patent matters.

Complementing his trial work, Rob advises clients on their patent strategies, including strategic portfolio management, licensing and transactional activities, and IP due diligence.

Rob has been recognized as a leading patent litigator by both the Legal 500 (2022) and IAM Patent 1000 (2022), which noted his “outstanding winning record” in pharmaceutical and biotechnology litigation.




231005_O'Melveny-Myers-LLP_Pete Herrick.jpg   

Partner
(O'Melveny & Myers LLP)

Peter Herrick has represented clients in complex and challenging transactions and antitrust litigation for nearly 20 years. Peter has tried six merger litigations to final decisions, both for and against the government, including groundbreaking cases on behalf of the Federal Trade Commission. In addition to representing clients on mergers and acquisitions before the FTC, Department of Justice, and other antitrust regulators, Peter leads high stakes antitrust litigation for clients in federal court. Clients trust Peter’s strategic approach to both transactions and disputes, value his clear judgment, and depend on his credibility both in court and before the antitrust agencies.

Prior to returning to private practice, Peter was Senior Trial Counsel in the FTC’s Bureau of Competition. In that role, Peter co-led the FTC's 18-day trial and victory in FTC et al. v. St. Luke's Health System, Inc. et al., the FTC’s first successfully litigated merger challenge of a hospital system’s acquisition of a physician group. While in the FTC’s Mergers IV Division, he was a key trial team member in the FTC's successful merger challenges in FTC v. Phoebe Putney Health System and FTC v. OSF Health System. While at the FTC, Peter received the Janet D. Steiger Award three times for his contributions to key litigations.



231005_O'Melveny-Myers-LLP_Stephen McIntyre.jpg   

Partner
(O'Melveny & Myers LLP)

Stephen McIntyre is a versatile antitrust lawyer who represents clients in civil and criminal investigations, government enforcement actions, and high-stakes private litigation. Stephen brings skill, insight, and practicality to each matter—be it a nationwide class action, a suit against a client’s chief competitor, or an inquiry from a federal or state antitrust enforcer.

Stephen has secured victories for clients in the pharmaceutical, technology, and entertainment industries, among others. His recent successes include a Ninth Circuit victory affirming the dismissal of antitrust conspiracy claims against manufacturers of dynamic random access memory (DRAM) chips; a sweeping summary judgment win on behalf of ExxonMobil in an antitrust conspiracy case in which plaintiffs sought tens of billions of dollars in damages; the complete dismissal of monopolization and “reverse-payment” claims in In re Humira, an antitrust case involving the world’s highest-selling biologic drug; and an across-the-board summary judgment win in In re Optical Disk Drives, a consumer class action in which plaintiffs sought billions in alleged damages from major electronics companies.


Click here for more information of O'Melveny & Myers LLP 





Vlad-square.png

Vlad Lobatchev
Director of Engagement Management and Data Science
(FRONTEO USA)

As an Engagement Manager and a Director of Data Science and Strategy, Vlad Lobatchev is responsible for ensuring that our clients always receive top-tier customer experience and best-in-breed technology to enhance their e-Discovery workflows. He draws on his extensive professional experience and legal background to guide development and implementation of innovative technological solutions and workflows on client engagements. Prior to joining FRONTEO, he was an attorney for two years specializing in general corporate and finance law – taxation, contracts, corporate formation, and administration.


◆Moderator:

Shiho- square2.png

Shiho Tanaka
SVP, Discovery Consulting Division (FRONTEO USA)


Registration for this seminar has closed.

Registration for this seminar has closed.